PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Digital Health Global
FEBRUARY 27, 2024
This game-changing technology is now poised to address the needs of pediatric patients with ADHD in Japan if approved, and this exciting milestone is yet another example of PureTech’s contribution to changing the lives of patients in need.” “We are pleased by this additional validation of Akili’s EndeavorRx,” said Eric Elenko, Ph.D.,
Let's personalize your content